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cytes in the walls of the capillaries and venules. This tumor is reported to occur
mostly in lower extremity and retro peritoneum with rare occurrence in the head
and neck region. Generally they are slow growing, locally infiltrative and aggressive,
with various rates of pleomorphism and malignant potential. Clinical presentations
of these tumors are characteristically non-specific and diagnostic modalities are of
little help. Surgery remains the gold standard of the treatment with additional ben-
efits if adjuvant RT is taken. Here we report a case of haemangiopericytoma arising
in the base of the tongue with a brief review of the literature. To our knowledge this
is the first case in this location to be reported in the English literature.c 2005 Published by Elsevier Ltd.
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bIntroduction
Haemangiopericytoma (HPC) is an uncommon neo-
plasm first described by Stout and Murray in 1942.1
It arises from pericytes1–7 which are slender elon-
gated cells located in the walls of capillaries and
venules. These cells are external to the endothelial741-9409/$ - see front matter c 2005 Published by Elsevier Ltd.
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They are considered undifferentiated cells that
can differentiate into other cell types including
smooth muscles.3,4 This tumor has been reported
to occur mostly in the lower extremity and retro
peritoneum.1–7 About 15–20% of cases have been
reported in the head and neck region8 including
orbit, nasal cavity, paranasal sinuses, nasopharynx,
buccal mucosa, lip, floor of the mouth, gum, man-
dible, salivary gland and larynx.2,3,5,9–12
Here we are presenting the first case to be re-
ported of haemangiopericytoma of base tongue in
2 S. Sharma et al.a young adult male. In our review of literature we
found no reference regarding haemangiopericy-
toma of base tongue in adults.Figure 2 Intra operative photograph showing trans-
hyoid approach for BOT tumor.Case report
A healthy male aged 32 years presented with com-
plaints of throat pain, change in voice and gradu-
ally increasing dysphagia. Past history was not
suggestive of any previous medical illness or
surgery. On examination there was no palpable
mass in the neck and no cervical lymphadenopathy.
All blood investigations were within normal limits,
the chest skiagram was normal. Barium swallow
showed mass in the oropharynx (Fig. 1). On indirect
laryngoscopic examination there was an exophytic
friable, fleshy growth in front of the epiglottis.
There was no clinical or radiological evidence of
distant metastases from the tumor. On direct
laryngoscopic examination under general anaesthe-
sia there was a large exophytic friable vascular
growth arising from the central part of the BOT
(base of tongue) rest of oropharynx, hypopharynx
and glottis were normal. Histological picture
showed sheets of spindle cells having scanty cyto-
plasm and plump nucleus. Tumor also showed
prominent vessels and mitoses seen were 3–4/10
HPF. Overall the picture was of spindle cell sar-
coma highly suggestive of haemangiopericytoma.
Subsequently for management the patient
underwent wide excision of BOT tumor by transhy-
oid pharyngotomy through vallecula, by a trans-
verse neck incision at the level of hyoid bone
under GA with nasotracheal intubation (Fig. 2).
There was a pedunculated exophytic friable mass
arising from BOTmeasuring 6 cm · 5 cm. Wide exci-
sion of growth was carried out with margin of 1 cm
of normal BOT. Margins of resections were con-Figure 1 Barium swallow showing mass lesion in the
oropharynx.firmed by intra operative frozen section and were
found to be negative for tumor cells. Resulting
defect in BOT was closed primarily by absorbable
sutures. Patient had uneventful post-operative
recovery and was discharged on the 10th day.
On gross examination of the specimen tumor was
6 cm · 5 cm · 1.5 cm in size, cut surface was
white, firm and some areas showed papillary
appearances and scattered areas of necrosis and
haemorrhage. Microscopic examination showed
spindle to oval shaped cells with scanty cytoplasm
and plump nucleus (Fig. 3). Tumor showed exten-
sive staghorn vascular pattern (Fig. 4), mitoses
were 4–5/10 HPF. There were focal myxoid
changes and haemorrhagic areas. PAS and reticulin
staining showed prominent vascular pattern.
Cells were negative for Manson Trichrom stain.
On immunohistochemistry tumor cells showed
vimentin and actin positivity and were negative
for Factor VIII.Figure 3 Photomicrograph showing oval shaped cells
with scanty cytoplasm and plump nucleus.
Figure 4 Photomicrograph showing prominent vessels
with staghorn pattern (H&E Stain low power 10·).
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dence of recurrence.Discussion
Haemangiopericytoma is an uncommon mesenchy-
mal vascular neoplasm that is reported with rare
occurrence in head and neck region. Nasal cavity
and paranasal sinuses are the most common sites
of presentation5,15 while oropharynx remains the
rarest. This is a tumor of unknown etiology
although various factors like previous trauma, ste-
roid use and genetic factors have been suggested to
cause this.13
HPC many occur at any age, more commonly in
4th or 6th decade1,2,4,5,7,13 with no racial or sexual
preponderance.1,2,4,5,13 Clinical presentation of
HPC are characteristically non-specific.1,2,4–7,13 It
mostly presents as slow growing painless mass asso-
ciated with only local symptoms. Pain usually oc-
curs in advanced cases and most often caused by
pressure over neurovascular structures.1,2 Hypogly-
cemia has been reported in few cases of HPC in
which blood sugar level came back to normal after
resection of tumor.2,4,6
Rontegenographic features are not specific for
HPC and consists of radioopaque soft tissue mass
displacing neighbouring structures.1,2 Focal calcifi-
cation has been also reported.1,2 Daniels et al.,
after reviewing radiological literature evaluating
HPC from many anatomic sites reported CT, MRI
and angiographic features of HPC.13 In cases of
HPC, consistent CT findings were hypervascularity
with enhancement and well circumscribed margins.
Both of these findings are non-specific.13 MRI find-
ings are of a well circumscribed vascular tumorsuggestive of HPC and further clarifies the bound-
aries and plane of tumor extension.2,5,7,13,14 Angi-
ography shows a characteristic filling showing a
dense well circumscribed stain secondary to accu-
mulation of contrast in tumor capillary network.13
Overall angiographic picture of HPC is of a richly
vascular tumor with dilation of the regional arter-
ies in the arterial phase, diffuse capillary blush
and dilation of draining veins in the late capillary
phase.2,7 Angiogram does not differentiate HPC
from other richly vascular soft tissue neoplasm
but helps in narrowing down the diagnostic possi-
bilities.2,7,13,15 According to one report absence
of early venous filling in HPC is highly noteworthy
and it differentiates HPC from other malignant soft
tissue and benign vascular tumors.7 Diagnostic
imaging studies are employed in cases of HPC for
anatomic delineation, narrowing down the list of
most probable diagnoses, defining the local extent
as well as relationship to vital structures and iden-
tification of distant metastasis.2,13–15 MRI and
angiographic findings are therefore useful in plan-
ning and execution of effective surgical ap-
proaches.2,3,13–15
HPC has a uniquely variable range of malignant
potential.1,2,4,5,14,16 Tumor may be classified as
‘benign’, ‘borderline malignant’ and ‘malignant’
on the basis of histological findings.1,4,5,14 An asso-
ciation has been suggested between hypercellular-
ity, mitotic activity anaplasia, necrosis and
haemorrhage with more malignant HPC.1,2,4,5,14,16
Enxinger and coworker have reported that tumor
having 0–4 mitoses per 10 HPF have 77% 10 year
survival while tumors having >4 mitoses per 10
HPF have 29% 10 year survival. They have also re-
ported that tumors having <6.5 cm diameter have
92% 10 year survival.4,14
HPC have high rate of local recurrence and dis-
tant metastases to lung and skeleton as most fre-
quent sites.1,2,4,5,14 Enxinger and coworker have
considered lymphnode metastases to be rare but
others have reported metastases to lymphnode
also.5,12,16,17 Metastatic rates for borderline and
malignant variety has been reported to be 45%.5
Blackwinkle and Diddans in comprehensive re-
view of 224 cases reported that haemangiopericy-
toma is highly malignant over a life time in about
50% of cases.5,6 Latency period of HPC recurrence
have been reported upto 16 years to 33 years,
although peak incidence of recurrence is between
1 and 5 years1,5,6,14 and varies with particular organ
system involved. They have reported recurrence
rate of 80% in tumors of CNS and 50.5% for tumors
of musculoskeletal system.5,6
As this tumor is not of a common occurrence
with the biological behaviour quite unpredictable,
4 S. Sharma et al.management of this tumor has been a subject of
debate. Surgery is considered the standard therapy
whenever tumor is technically resectable. Consen-
sus in the literature is to treat all resectable HPC
with wide excision.1–6,10,14,15,17,18 Local recur-
rence and solitary metastasis have also been widely
excised with prolonged survival.14 Pre-operative
tumor embolization has been suggested to be a
useful procedure having value in helping to reduce
blood loss during surgery which allows aggressive
resection of large tumors especially in retroperito-
neum and visceral sites.3,14,15
Initial report regarding use of RT as primary or
adjuvant therapy were not very encouraging how-
ever, recent reports have documented tumor re-
sponse to doses >45 Gy2–4,14,18 thereby suggesting
RT to be a useful adjunct to wide excision as it have
been reported to reduce rates of local recur-
rence.2,3,14,18 It has been also suggested that RT is
useful in unresectable or recurrent tumor for pur-
pose of palliation.1,17,18 Mira et al. have suggested
that bulky resectable tumors should be excised
whenever possible prior to radiation therapy.18
Chemotherapy has not been found to be useful
as adjuvant or primary therapy.1–3,14 Partial or
short term remission of metastatic tumor have
been reported with doxorubicin as single agent or
in combination therapy.2,3,14,19 However, long
term remission or survival is not reported.
At present, surgery i.e. wide excision is the stan-
dard treatment. Additional benefits may be gained
by the use of adjuvant RT. Treatment outcome how-
ever depends on tumor size, the number of mitotic
figures per 10 HPF and the histological grade with
newer technologies coming up, early detection and
effective treatment options have now become
possible. However, close regular follow up of the
patients is required for long duration for early detec-
tion and effective management of recurrence.References
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